The global market for products treating heart valve disease is expected to exceed $8bn by 2021, driven largely by the rising number of elderly patients with cardiovascular disease, obesity and growing prevalence of diabetes. This, in turn, is fueling significant innovation in minimally invasive techniques, particularly in the leading area of transcatheter aortic valve replacement (TAVR), but also in transcatheter mitral valve repair (TMVrep) systems, both of which offer patients quicker recovery times, less discomfort and greater safety compared to traditional surgical heart valve repair and replacement. This feature looks more closely at the competitive landscape and dynamics of these two fast-growing market segments, as well as gives insight into what the users – the physicians – think of these technologies.
Heart valve repair is growing, boosted by the ageing population
The global market for products treating heart valve disease is forecast to grow from $4.8bn in 2016 to $8.1bn in 2021, at a compound annual growth rate (CAGR) of 10.9%. According to Meddevicetracker's "Heart Valve Repair And Replacement Market" report, sales of traditional devices used in open heart valve repair and replacement procedures accounted for about 41% of total product sales in 2016, as it gets overtaken by transcatheter technologies – a field currently dominated Edwards Lifesciences Corp., Medtronic PLC and St. Jude Medical Inc. /Abbott Laboratories Inc. – which held 59% of the total market.
By 2021, Meddevicetracker expects new technological advancements and continued expansion to a wider, younger patient population will significantly drive up market share of emerging transcatheter devices to 76% whereas the...
